137 related articles for article (PubMed ID: 26410019)
1. "Score the Core" Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring.
Engelberg JA; Retallack H; Balassanian R; Dowsett M; Zabaglo L; Ram AA; Apple SK; Bishop JW; Borowsky AD; Carpenter PM; Chen YY; Datnow B; Elson S; Hasteh F; Lin F; Moatamed NA; Zhang Y; Cardiff RD
Hum Pathol; 2015 Nov; 46(11):1694-704. PubMed ID: 26410019
[TBL] [Abstract][Full Text] [Related]
2. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
[TBL] [Abstract][Full Text] [Related]
3. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
Oluwasola AO; Malaka D; Khramtsov AI; Ikpatt OF; Odetunde A; Adeyanju OO; Sveen WE; Falusi AG; Huo D; Olopade OI
Ann Diagn Pathol; 2013 Dec; 17(6):526-30. PubMed ID: 24095629
[TBL] [Abstract][Full Text] [Related]
4. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Fu P; Honda Y; Iyama K; Iwase H
Mod Pathol; 2013 Jan; 26(1):79-86. PubMed ID: 22918168
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M
Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828
[TBL] [Abstract][Full Text] [Related]
7. Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.
Lee J; Kim WH; Jung JH; Kim WW; Park CS; Lee RK; Park JY; Chae YS; Lee SJ; Kim HJ; Park JY; Park HY
In Vivo; 2019; 33(6):2133-2139. PubMed ID: 31662548
[TBL] [Abstract][Full Text] [Related]
8. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.
Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW
Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737
[TBL] [Abstract][Full Text] [Related]
9. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Image Analysis as an Adjunct to Manual Scoring of ER, PgR, and HER2 in Invasive Breast Carcinoma.
Yousif M; Huang Y; Sciallis A; Kleer CG; Pang J; Smola B; Naik K; McClintock DS; Zhao L; Kunju LP; Balis UGJ; Pantanowitz L
Am J Clin Pathol; 2022 Jun; 157(6):899-907. PubMed ID: 34875014
[TBL] [Abstract][Full Text] [Related]
11. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
12. Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment.
Orlando L; Viale G; Bria E; Lutrino ES; Sperduti I; Carbognin L; Schiavone P; Quaranta A; Fedele P; Caliolo C; Calvani N; Criscuolo M; Cinieri S
Breast; 2016 Dec; 30():151-155. PubMed ID: 27750105
[TBL] [Abstract][Full Text] [Related]
13. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
[TBL] [Abstract][Full Text] [Related]
14. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma.
Ronchi A; Pagliuca F; Zito Marino F; Accardo M; Cozzolino I; Franco R
Semin Cancer Biol; 2021 Jul; 72():114-122. PubMed ID: 32165319
[TBL] [Abstract][Full Text] [Related]
15. Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis?
Altundag K
J Neurooncol; 2018 May; 138(1):219. PubMed ID: 29383648
[No Abstract] [Full Text] [Related]
16. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
18. Noninferiority of Artificial Intelligence-Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics.
Abele N; Tiemann K; Krech T; Wellmann A; Schaaf C; Länger F; Peters A; Donner A; Keil F; Daifalla K; Mackens M; Mamilos A; Minin E; Krümmelbein M; Krause L; Stark M; Zapf A; Päpper M; Hartmann A; Lang T
Mod Pathol; 2023 Mar; 36(3):100033. PubMed ID: 36931740
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
